美泊利单抗降阶梯治疗嗜酸性肉芽肿性多血管炎:一项真实世界单中心研究
该回顾性单中心研究纳入2014年4月至2024年12月接受美泊利单抗治疗的嗜酸性肉芽肿性多血管炎(EGPA)患者,评估从高剂量(300 mg/4周)降阶梯至低剂量(100 mg/4周)的疗效与安全性。45例初始接受300 mg/4周的患者中,12例(27%)在中位26.5个月后转为100 mg/4周;降阶梯后中位随访27.5个月期间,50%的患者维持完全缓解且未用糖皮质激素,50%出现鼻窦鼻腔症状复发并接受增加美泊利单抗剂量或优化局部治疗,无哮喘或血管炎加重。
要点
- 45例初始接受美泊利单抗300 mg/4周的患者中,12例(27%)在中位26.5个月后降阶梯至100 mg/4周。
- 降阶梯后中位随访27.5个月,50%的患者维持完全缓解且未用糖皮质激素。
- 50%的患者鼻窦鼻腔症状复发,接受增加美泊利单抗剂量或优化局部治疗,无哮喘或血管炎加重。
核心结论
- 初步数据显示,美泊利单抗降阶梯至100 mg/4周可有效维持EGPA患者的全身缓解并减少糖皮质激素使用,但鼻窦鼻腔症状复发提示需要个体化管理。
- 作者认为需要更大规模的研究来证实这些发现并优化长期治疗的给药策略。
研究设计与样本
- 回顾性单中心研究,纳入2014年4月至2024年12月接受美泊利单抗治疗的EGPA患者。
- 降阶梯治疗的患者需处于缓解状态,定义为伯明翰血管炎活动评分(BVAS)为0、哮喘控制测试(ACT)>20且无激素治疗至少一年。
- 通过病历追踪疾病活动度、嗜酸性粒细胞计数和全身糖皮质激素(GC)使用情况。
主要发现
- 45例初始接受300 mg/4周的患者中,12例(27%)在中位26.5个月后转为100 mg/4周。
- 降阶梯后中位随访27.5个月期间,50%的患者维持完全缓解且未用GC治疗。
- 50%的患者鼻窦鼻腔症状复发,接受增加美泊利单抗剂量或优化局部治疗。
- 未发生哮喘或血管炎加重。
关键数值与推荐
- 缓解定义:BVAS为0、ACT>20且无激素治疗至少一年。
- 高剂量为300 mg/4周,低剂量为100 mg/4周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论称初步数据,需更大规模研究证实并优化长期给药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of a step-down treatment approach using mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) in a real-life single-centre cohort. The study aimed to assess outcomes following a transition from high-dose (300 mg/4 weeks) to low-dose (100 mg/4 weeks) mepolizumab after achieving remission. METHODS: This retrospective study included EGPA patients treated with mepolizumab between April 2014 and December 2024. Patients receiving step-down therapy were in remission, defined by a Birmingham Vasculitis Activity Score (BVAS) of 0, Asthma Control Test (ACT) >20 and steroid-free for at least one year. Disease activity, eosinophil counts and systemic glucocorticoids (GC) use were tracked in medical charts. RESULTS: Among 45 patients initially treated with 300 mg/4 weeks, 12 (27%) switched to 100 mg/4 weeks after a median of 26.5 months. Over a median follow-up of 27.5 months post-step-down, 50% maintained complete remission without GC therapy. In 50% of patients sinonasal symptoms recurred and were treated with either increased mepolizumab dose or optimization of local therapy. No asthma or vasculitis exacerbations occurred. CONCLUSION: Our preliminary data show that step-down therapy with mepolizumab to 100 mg/4 weeks was effective in maintaining systemic remission and reducing GC use in EGPA patients. However, recurrence of sinonasal symptoms suggests the need for an individualized management. Larger studies are warranted to confirm these findings and optimize dosing strategies for long-term care.
引用
- Moroni L, Batani V, Gallina GD, et al. Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study. Rheumatology (Oxford). 2025. PMID: 40221861. doi:10.1093/rheumatology/keaf201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。